Critical limb ischemia in diabetic patients is associated with high rates of morbidity and mortality. Suboptimal responses to the available medical and surgical treatments are common in these patients, who also demonstrate limited vascular homeostasis. Neovasculogenesis induced by stem cell therapy could be a useful approach for these patients. Neovasculogenesis and clinical improvement were compared at baseline and at 3 and 12 months after autologous bone marrow-derived mononuclear cell (BMMNC) transplantation in diabetic patients with peripheral artery disease. We conducted a prospective study to evaluate the safety and efficacy of intra-arterial administration of autologous BMMNCs (100-400 × 10 6 cells) in 20 diabetic patients with severe below-the-knee arterial ischemia. Although the time course of clinical effects differed among patients, after 12 months of follow-up all patients presented a notable improvement in the Rutherford-Becker classification, the University of Texas diabetic wound scales, and the Ankle-Brachial Index in the target limb. The clinical outcome was consistent with neovasculogenesis, which was assessed at 3 months by digital subtraction angiography and quantified by MetaMorph software. Unfortunately, local cell therapy in the target limb had no beneficial effect on the high mortality rate in these patients. In diabetic patients with critical limb ischemia, intra-arterial perfusion of BMMNCs is a safe procedure that generates a significant increase in the vascular network in ischemic areas and promotes remarkable clinical improvement.
INTRODUCTION
of arteriolar enlargement and the formation of collateral vessels that connect preocclusive arteries to the diseased intraischemic arteries (29) . Both mechanisms of com-Peripheral artery disease (PAD) is a common and severe complication of diabetes mellitus and shows high pensatory neovasculogenesis are impaired in diabetic patients due to endothelial progenitor cell dysfunction; rates of short-term morbidity and mortality. PAD in diabetic patients shows a distinctive pattern with occlusive this impairment explains the early extensive and accelerated process of vascular complications in diabetes melli-arterial lesions that are typically located distally below the knee (BTK); this limits the possibility of successful tus (12, 20, 31) . The number of peripheral endothelial progenitor cells in both type 1 and type 2 diabetic pa-mechanical revascularization by either surgical or endovascular methods (6, 7) . Neovasculogenesis, which is the tients is decreased by more than 40% and is correlated with an increase in glycosylated hemoglobin (HbA1c) development of a new vascular network, is a physiological response to chronic ischemia and comprises two dif- (11, 20) . Subsequently, PAD is associated with a very low number of endothelial progenitor cells in peripheral ferent processes: angiogenesis and arteriogenesis. Angiogenesis consists of the sprouting of capillaries and the blood (11) . Stem cell revascularization therapy for the treatment formation of a capillary network that grows within an ischemic area. In contrast, arteriogenesis is the process of diabetic nonrevascularizable PAD is a recent approach 1630 RUIZ-SALMERON ET AL. (24, 28) . In addition, most of the studies conducted to Dislipidemia (%) 11 (55%) date are based on surrogate endpoints that reflect changes Hypertension (%) 15 (75%) in limb perfusion and very few reports are available that tice principles (32) . Furthermore, an increase in HbA1c
Rutherford Becker correlates with a decrease in endothelial progenitors Category 4 3 (15%) (11, 20) , which means that diabetic patients with HbA1cs
Category 5 11 (55%) above 6.5% were excluded from previous studies. Our population sample was composed of 20 patients with severe limb ischemia, with no options of revascularization, who were treated with autologous BMMNC preparation. In the case of bilateral limb ischemia, the vascular work-up, which included measurement of systolic blood pressure at both the anterior and posterior target limb used in the study was the more severely affected limb. All patients provided written informed con-tibial arteries, measurement of ABI, which is the quotient of the highest ankle pressure and the highest bra-sent and fulfilled the inclusion criteria (Table 1) . Of these patients, 11 (55%) had undergone failed attempts chial systolic blood pressure and imaging studies that consisted of conventional intra-arterial digital subtrac-of revascularization using PTA/stents or bypass in the ischemic limb and 9 (45%) presented no run-off and tion angiography. Transcutaneous partial oxygen tissue pressures (tcpO 2 ) in the supine position were recorded were not suitable for revascularization. CLI was diagnosed according to the recommendations of the current using an oxygen monitor (TCM400 Radiometer, Copenhagen, Denmark). To assess the severity of limb ische-TransAtlantic Inter-Society Consensus (TASC) (23) .
Assessment of the peripheral circulation of patients mia, we followed the classification system proposed by Rutherford et al. (26) ; wounds were graded and were was performed at baseline and at 3 and 12 months, respectively. This consisted of a complete noninvasive staged according to University of Texas Diabetic Wound Classification System (18). All patients were evaluated tion of ABI changes at the 3-month follow-up and the changes in the Rutherford-Becker and University of on a case-by-case basis by a dedicated multidisciplinary vascular team that included interventional radiologists Texas classifications during the course of the study compared to baseline values (obtained at the time of infu-and vascular surgeons. sion).
Autologous BMMNC Preparation
Angiographic Quantification of Neovascularization The process of BMMNC preparation and administration was performed completely within the catheteriza-For each patient, a comparison of lower limb digital subtraction angiography (DSA) images between baseline tion laboratory surgical room. After mild sedation and local anesthesia, the iliac crest was punctured and aspi-and at the 3-month follow-up was performed. Both DSA acquisitions were performed by a vascular fluoroscopic rated to obtain 60 ml of bone marrow preparation. This sample was diluted in 40 ml of heparinized saline (20 UI imaging system (Infinix, Toshiba, Japan) and were focused on the BTK area; measurements were obtained nonfractionated heparin/ml). BMMNCs were separated with a Ficoll density gradient (Amersham Pharmacia Bio-under the same acquisition and procedural parameters (level of injection and contrast flow). DSA acquisitions tech, Uppsala, Sweden) and washed in PBS (Sigma, St. Louis, MO, USA). Prior to the administration of the were sent to a core-lab (CABIMER, Seville Spain) for quantitative analysis; a common area was selected for BMMNCs, the number of mononuclear cells and their viability was determined and a sample of 0.5 ml was quantification ( Fig. 1A ). Quantitative analysis of the resulting images was performed using MetaMorph v.6.3 obtained for determination of the percentage of CD34 + cells by flow cytometry analysis (Citomics FC 500 using the Angiogenesis Tube Formation application module. Minimum and maximum width vessels were Beckman-Coulter). Finally, BMMNCs were filtered through a cell strainer and diluted in 20 ml of saline to initially empirically chosen to fit angiographic value ranges from 0.5 to 6 mm (thinnest to thickest tubule, fill a 50-ml syringe that was kept sealed until administration. respectively). Analysis was performed using four intensity values above the local background (400, 600, 800, Intra-arterial Administration of BMMNCs and 1000 gray levels). As shown in Figure 1B , the final process of quantification generated a segmented image While the BMMNCs were being processed, target limb arteries were selectively cannulated through a [16-bit autoscaled image where a value of 2 (white) represents the vessels and a value of 1 (green) represents transfemoral or transradial approach with an over-thewire catheter balloon that was advanced as distally as the nodes]. The numeric results are presented as mean ± SEM of the intensity values above local background for possible and positioned proximal to the occlusive vascular lesions, usually at the distal femoral or popliteal ar-each parameter. Statistical significance was assessed by using a paired difference mean of each parameter paired-tery. At this point, the balloon was inflated to block antegrade blood flow and the BMNMCs were slowly samples t-test (sig. two-tailed). The assessment of the vascular network was focused on the measurement of its infused for 3 min. After infusion, the balloon was deflated and antegrade blood flow was restored. The num-extension and density: the extension of vascularity was the sum of the arterial length (total tubule length) or the ber of BMMNCs obtained ranged from 113.7 × 10 6 to 434.5 × 10 6 (mean 266.2 ± 81.89 × 10 6 ). The amount of arterial area (total tubule area); the vascular density, which expressed the sprouting and vascular network for-CD34 + cells was 1.73 ± 0.43%, which resulted in a mean infusion of 4.37 ± 1.54 × 10 6 CD34 + cells (ranging from mation, was measured by counting the number of segments (total number of vessel segments connecting 2.14 × 10 6 to 7.81 × 10 6 cells). The site of BMMNC infusion was distal femoral artery in 1 patient, popliteal branch points and/or ends) and the number of branch points (total number of junctions connecting segments). artery in 13 patients, and BTK in 6 patients. In 6 patients, the procedure was performed using a transradial
The schematic illustration of those parameters is indicated in Figure 1C . Neovascularization was character-approach that required extra-large over-the-wire balloons of 200-cm length.
ized as a significant increment of extension and/or density of the vascular network at the 3-month follow-up Evaluation of BMMNC Transplantation Efficacy compared to baseline. The efficacy of BMMNC transplantation was as-Safety Assessment sessed by the development of neovascularization downstream of the site of cell infusion. The primary endpoint The safety assessment checked for possible adverse events related to the intra-arterial infusion of BMMNCs, was the angiographic evaluation of neovascularization, with quantification of vascular network growth at the 3-which was initially performed 24 h after the procedure, focused on the risk of thrombogenic events. These as-month follow-up. Secondary endpoints were the evalua- sessments were then followed up with planned clinical rovascular disease; 7 patients were referred with symptomatic vascular disease other than PAD (coronary and visits at 1, 3, and 12 months after the procedure; severe adverse events were reported to the promoter of the cerebrovascular) and all the patients presented with bilateral limb symptoms at baseline. The mean ABI re-study.
sults, as an expression of limb perfusion, reflected the RESULTS severity of the clinical manifestations for both limbs: 0.49 ± 0.23 for the right limb and 0.56 ± 0.17 for the left Baseline Clinical Characteristics one. Selected target lower limbs (14 right and 6 left Twenty patients ( Table 1 ) average age of 64 ± 6 lower limbs) were severely symptomatic (100% of payears old (51-75 years old), who consisted of 18 males tients had Rutherford-Becker category of 4/6), with a and 2 females, were included. All but one patient (P13) mean ABI value of 0.46 ± 0.19. In most patients, the had type 2 diabetes. Diabetes treatment consisted of incontralateral extremities were also affected, although sulin in 13 patients (in 2 patients, this was administered they were less symptomatic. The University of Texas in combination with oral antidiabetic agents) and antididiabetic wound classification showed unhealed ulcers abetic oral agents alone for the remaining 7 patients. The for 11 patients (7 grade C3, 3 grade C2, and 1 grade mean glycosylated hemoglobin was 7.7 ± 1.0% (ranging A2). The remaining 9 patients displayed healed trophic from 5.7 to 9.7%), which is a value similar to that relesions at the start of the trial and target limbs were clasported to induce impaired proliferation, adhesion, and sified as C1, C0, and A0, with 3 patients for each cateincorporation of endothelial progenitor cells into vascugory. lar structures (31) . The majority of our patients suffered severe microvascular complications: diabetic neuropathy Quantitative Assessment of Neovascularization (25) in 17 patients, retinopathy in 12, and diabetic nephropathy in 4 patients (no patient was undergoing Systematic angiographic review to evaluate BTK neovascularization was performed before and 3 months hemodialysis). There was also extensive spread of mac-after the infusion of BMMNCs for all patients, except routine quantitative analysis was performed to assess neovascularization. MetaMorph software was used to for one, who died before angiographic follow-up. Comparison of angiographic images showed a widespread evaluate the development of a vascular tree downstream of the site of cell infusion to provide information about improvement in BTK vascularization ( Fig. 2A) downstream of the site of cell administration (Fig. 2B) . Vas-the extension of vascularity and the density of the vascular network. Neovascularization was considered as the cular improvement presented two patterns, which were usually combined. One pattern was the development of net improvement in vascular extension and/or the density at the 3-month follow-up compared to baseline. a vascular network, which expanded from the main vessels (tibial anterior, tibial posterior, or peroneal arteries) Quantification showed that substantial neovascularization was achieved by the majority of patients: 13 pa-to the periphery of the calf that was comprised of tapered and highly branched vessels that reached the sub-tients (68%) at the 3-month follow-up showed an improvement in vascularity with an increase in vascular cutaneous tissue; the other consisted of an increase in the diameter of collateral preexisting vessels. Another extension and/or vascular density variables. Regarding variables that measured vascular extension, at the 3-angiographic finding, which was detected in 3 patients (P4, P9, and P13), was the development of a rapid (fistu-month follow-up, there was a significant increase in the overall length of the vessels in 11 patients (58%), lous) arteriovenous transition, with simultaneous filling of downstream arteries and upstream venous drainage;
whereas 10 patients (53%) presented with significant increases in total vessel area. Regarding the density of the this unexpected finding was particularly remarkable in one patient (P9), which showed the presence of multiple sprouting network vascularity, at the 3-month follow-up 11 patients (58%) presented with significant increases in structures with the appearance of angioma-like structures (defined as a rapid arteriovenous transition during the the total number of vessel segments connecting branch points and/or ends; 10 patients (53%) presented with early phase of arteriography that showed unique or multiple focal contrast-enhanced formations, as assessed by significantly increased branch point variables (the total number of junctions connecting segments). Thus, the angiographic analysis) ( Figure 3A) . These patients did not present with any clinical complications at follow-up.
overall quantification of our population showed a statistically significant increase in vascular extension [total Besides this visual assessment of vascularization, a 
(B) Angiographic data of vascular extension (total tube area and length) and vascular density (junction or branch points and vascular segments) at below-
the-knee vascular region were quantified and compared between baseline (black) and 3 months follow-up (gray). There was significant increase of each variable, which expresses the appearance of neovascularization induced by intra-arterial administration of autologous BMMNCs. Statistical significance was assessed by using a paired samples t-test (sig. two-tailed). tubules length and total tubules area with a paired differ-superficial ulcer (A1) located on the first toe. Referring physicians reported that the infusion of BMMNCs in-ence mean of 196.33 mm, sig. 0.00022 (two-tailed), and 444.57 mm 2 , sig. 0.002 (two-tailed), respectively] and duced an unexpected benefit of an improvement in the healing process, not only for ulcers ( Fig. 4B ), but even sprouting network [segments and branch point with a paired difference mean of 28.89, sig. 0.00017 (two-tailed) for minor amputations. Furthermore, early clinical benefits of cell infusion consisted of patients having a wide-and 11.53, sig. 0.00015 (two-tailed), respectively] (Fig. 3B) .
spread perception of less limb pain, an increase in pain-Clinical Changes Induced by BMMNCs free walking, and warmness in the target limb. At the 3month follow-up, patients (one deceased, P16) mani-One year after BMMNCs infusion, there was a remarkable improvement in clinical status in most of the fested clear clinical benefit, with the exception of two patients (P5 and P11) who also showed no angiographic target limbs. All 16 patients who were alive after the first year of follow-up presented with a notable improve-improvement. In addition to the clinical improvement for the majority of the sample population, there was a ment in both Rutherford-Becker and University of Texas classification ( Table 2 ). The University of Texas dia-significant increase in ABI (from 0.46 ± 0.19 to 0.70 ± 0.23, sig. 0.019) in the target limb at the 3-month fol-betic wound classification reflected complete healing of trophic lesions without signs of ischemia or infection in low-up ( Fig. 4C ) and even more at 12-month follow-up (from 0.46 ± 0.19 to 0.81 ± 0.19, sig. 0.000). The tcpO 2 every patient, except for one (P9), who presented with a increased in most patients and also for those with tcpO 2 < 30 mmHg (22 ± 4 mmHg at baseline vs. 40.6 ± 18.3 at 
Safety Assessment
In this scenario, the clinical benefits of stem cell therapy have been reported in several studies. The Thera-No procedural complications during the cell adminispeutic Angiogenesis by Cell Transplantation trial tration were reported: even in low-perfusion areas, the (TACT) was the first study that demonstrated an effecinfusion of BMMNCs did not cause any embolic events.
tive role of the intramuscular administration of BMMNCs During the first year, there were no adverse events difor CLI, with a transient (1 month and 6 months) imrectly related to BMMNCs transplantation. provement in the severity of rest pain (21,30). Moreover, Amann et al. showed that bone marrow cell transplanta-DISCUSSION tion improved leg perfusion and promoted leg salvage in patients with end-stage CLI caused by peripheral artery The results of our study strongly suggest that intra-arterial implantation of low doses of autologous BMMNCs disease (1) . Based on preclinical studies (19) , several unresolved issues still remain; these include the ideal into ischemic limbs of diabetic patients induces the development of significant and functional neovasculariza-type of cells (BMMNCs, CD34 + cells, mesenchymal stem cells, combinations) that should be used, the dose tion. To our knowledge, this is the first study in which the vascular area and vascular density in the ischemic and route of administration, and the profile of patients who may receive the greatest benefit. region has been quantified using MetaMorph software. Furthermore, the angiographic improvement observed
The main strengths of this study include the following: i) the target population was focused on diabetic pa-correlated well with the clinical benefit during the first year of follow-up. Interestingly, 5 patients continued to tients, whereas other studies recruited patients from different pathologies (Buerger, tromboangeitis obliterans, make notable clinical improvements after 2 years of follow-up.
diabetes mellitus, etc.); ii) intra-arterial administration of BMMNCs that was as distal as possible and was down-CLI represents a major concern due to its prevalence among diabetic patients, its poor prognosis, and its lim-stream of the diseased arterial bed; iii) the primary endpoint was the angiographic confirmation of neovasculari-ited treatment options (6, 7) . Surgical or endovascular revascularization options are limited due to the poor arte-zation in ischemic limb areas at the 3-month follow-up, which was quantified by MetaMorph software; and iv) rial outflow in diabetics (14). the dose used was 10 times smaller (2.66 ± 0.8 × 10 8 and 4 MethaMorph parameters improved) while patients with higher HbA1c showed a significant improvement cells) than the dose (1-5 × 10 9 cells) used in previous studies (1, 30) . Recent studies have proved the feasibility (ABI from 0.35 to 0.72; Rutherford-Becker categories 5/6 to 1/0; Texas from C2-A2-A0 to A1-A0; and 2-3 and the safety of intra-arterial administration of BMMNCs, single or combined with intramuscular infusion (3,13, MethaMorph parameters improved). These results suggest that functional endothelial progenitors from the 33). A recent clinical trial (13) that compared intraarterial BMMNC administration with intramuscular bone marrow (presumably devoid of the glycosylation damage) are fully operative in terms of neovasculariza-BMMNC administration showed no significant benefit of one of the other; however, there is a trend that favors tion. Besides this improvement in the majority of patients, the assessment of ABI also showed a significant the intra-arterial route in terms of pain relief and limb salvage. In our study, BMMNCs were infused down-increase at the 3-month follow-up compared to baseline. The appearance of angiomatous structures down-stream into lower limb arteries and, for all but one patient, cells were distally infused at the popliteal artery or stream of the BMMNC perfusion point could be a matter of concern. Vascular endothelial growth factor (VEGF) below while discontinuing antegrade blood flow for 3 min, which guaranteed homing of a greater number of gene therapy for CLI has been associated with the occurrence of angioma (16) . Administration of BMMNCs into BMMNCs to the ischemic target area.
To date, the assessment of the efficacy of cell therapy severe ischemic tissues with upregulated endothelial receptors to angiogenic cytokines could trigger a hyperac-in severe PAD was based on surrogate endpoints (relief of pain and decrease of amputation rate) or functional tive response in creating new vessels. Three patients presented with angioma-like structures, with high contrast tests (ABI and tcpO 2 ), which reflect the perfusion of the ischemic limb (1, 27) . None of the previous studies dem-intensity and rapid transition to venous circulation representing increased angiogenesis with low-resistance flow onstrated neovascularization in diabetic patients with CLI using a quantitative method. Neovascularization to adjacent venules; luckily these patients experienced no complications. As previously reported, 1-year mortal-may be demonstrated either directly or by angiographic follow-up or through the pathological examination of ity for patients with severe PAD is approximately 20% and is mostly dependent on cardiovascular complica-amputated limb samples (32) that are not obtained from the injection sites. In our study, MetaMorph software tions (1, 2, 14) . In our study, 4 deaths were registered during the first year. Exitus were due to cardiovascular enabled the quantification of the vascular tree (4,10,17). The majority of patients presented with a significant in-deaths that occurred at least 3 months after the procedure and were unrelated to BMMNCs therapy. However, crease in vascularity in the ischemic BTK areas after cell infusion; this increase in neovascularization was there was a significant increase in local neovasculogenesis for the majority of the patient population and the correlated with the clinical status, with notable symptomatic improvement in the target limb for all at the 1-subsequent decrease in the number of amputations (1) and overall mortality was similar to that reported in year follow-up. A widespread improvement in Rutherford-Becker grade, ABI, and an almost complete healing PAD (2, 14) . of previous diabetic trophic lesions in the lower extremi-CONCLUSIONS ties were observed 3 months and 1 year posttransplantation.
The following conclusions were drawn: 1) intra-arte-In contrast with other studies in which patients with rial transplantation of BMMNCs in diabetic patients HbA1cs above 6.5% were excluded (13,15,21,30), our with severe PAD is an effective approach that is associpatients displayed a broad range of HbA1c values (from ated with short-term induction of neovascularization; 2) 5.7% to 9.7%), which were quite similar to those inour population manifested clinical improvement in the cluded in the Amann et al. study (1) . This allowed us to lower limb, which included better ulcer healing, intest whether the baseline and follow-up value of HbA1c creased ABI values, increased leg temperature, and other determines the clinical outcome. A direct comparison local signs that are indirect indicators of collateral vessel between the patients with an HbA1c below 6.5% (P14, formation; 3) the dose used is 10 times smaller than that P17, and P19) and those with higher HbA1cs (P3, P9, used in previously published studies; 4) intra-arterial and P13) demonstrates that this is not the case. In both BMMNC transplantation is a safe procedure, with no groups, the HbA1c remained at the baseline values. We adverse events resulting from stem cell therapy; and 5) observed similar benefits in patients with all levels of diabetic patients with HbA1cs above 6.5% should not be HbA1c. However, in those patients with lower HbA1c excluded from these studies or from potential treatment. values, the clinical scores were almost returned to nor- 
